Adamis pharmaceuticals announces pricing of public offering of common stock

San diego, jan. 29, 2021 (globe newswire) -- adamis pharmaceuticals corporation (nasdaq: admp), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, announced today the pricing of its previously announced underwritten public offering of 40,540,540 shares of its common stock at a public offering price of $1.11 per share, resulting in gross proceeds of approximately $45,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the company. all shares of common stock to be sold in the public offering are being sold by adamis.
ADMP Ratings Summary
ADMP Quant Ranking